Regulatory
FDA Reviewers Raise No Major Concerns Over a Blood Test That Screens for Many Cancers
Ahead of a pivotal advisory meeting, FDA staff flagged no major problems with GRAIL’s Galleri — a single blood test that hunts for signals of dozens of cancers, many with no screening today.